Oral Antidiabetics
High-yield Verified · Oct 2026Prototype: metformin
Oral Antidiabetics are a class of medications used for type 2 diabetes.
Medical view: SGLT2 Inhibitors (heart failure) → mechanisms, drug comparisons and Step 1 pharmacology
Medical view: Metformin → mechanisms, drug comparisons and Step 1 pharmacology
Medical view: Sulfonylureas → mechanisms, drug comparisons and Step 1 pharmacology
Medical view: DPP-4 Inhibitors → mechanisms, drug comparisons and Step 1 pharmacology
Medical view: GLP-1 Receptor Agonists → mechanisms, drug comparisons and Step 1 pharmacology
A family of subclasses (biguanide, sulfonylureas, -gliptins, -flozins, incretin mimetics) that lower glucose by complementary mechanisms.
How it works in the body
The system involved, what goes wrong, and how the drug and body interact.
01 Type 2 diabetes is many broken levers, not one
Type 2 diabetes isn’t a single failed switch — it is several failing systems at once. The core problem is insulin resistance (muscle, fat, and liver stop responding to insulin) layered on a slow decline in beta-cell output. Piled on top: the liver over-produces glucose (unrestrained gluconeogenesis), the gut’s incretin hormones (which normally boost insulin after a meal) are blunted, and the kidney reabsorbs too much glucose back into the blood instead of spilling it.
That "many levers" picture organizes the whole class: each subclass of oral agent pulls a different lever, on a different organ. Understanding which organ a drug acts on tells you both how it lowers glucose and what its signature side effect will be. This is also why these drugs are often combined — they add up because they don’t overlap.
02 How each subclass works — and why hypoglycemia risk differs
Metformin (a biguanide, and the first-line agent) works mainly at the liver, telling it to make less glucose, and improves insulin sensitivity in muscle. Crucially, it does not force insulin out, so on its own it is unlikely to cause hypoglycemia. Sulfonylureas (glipizide, glimepiride, glyburide) act on the beta cell, squeezing out insulin — but they do this regardless of the blood glucose level (glucose-independent), which is exactly why they can drop the sugar too low and cause hypoglycemia and weight gain.
The newer subclasses were designed around that problem. DPP-4 inhibitors ("-gliptins") raise the gut’s own incretin hormones, which stimulate insulin only when glucose is high (glucose-dependent) — so they rarely cause lows and are weight-neutral. GLP-1 receptor agonists ("-tides," mostly injectable, with oral semaglutide the exception) mimic that incretin more powerfully, adding satiety and slowed gastric emptying for real weight loss; tirzepatide goes one step further as a dual GIP and GLP-1 receptor agonist, raising insulin and lowering glucagon in a glucose-dependent manner. SGLT2 inhibitors ("-flozins") ignore insulin entirely — they block the kidney’s glucose reabsorption so the patient excretes glucose in the urine. The -flozins also carry labeled heart-failure and kidney-protective benefits (chosen for those conditions even without diabetes), while semaglutide, liraglutide, dulaglutide and tirzepatide are labeled to reduce major adverse cardiovascular events (semaglutide also kidney-disease progression).
03 Why the adverse effects follow from the mechanism
Each signature harm traces straight back to the organ the drug acts on. Sulfonylureas force insulin even when it isn’t needed → hypoglycemia and weight gain. Metformin’s footprint in the gut causes GI upset and diarrhea (take it with food, titrate slowly), and over years it can cause B12 deficiency; its rare but serious danger is lactic acidosis when the drug accumulates because the body can’t clear it (kidney failure, hypoxic states, IV contrast, excess alcohol) — the basis of its boxed warning.
SGLT2 inhibitors dump sugar into the urine, so the genital area becomes a breeding ground → yeast and urinary infections, and rarely Fournier gangrene; the osmotic diuresis causes volume depletion, and a metabolic shift toward ketones can cause euglycemic DKA — ketoacidosis with a near-normal glucose, which is easy to miss. DPP-4 inhibitors and GLP-1 agonists can cause pancreatitis; semaglutide, liraglutide, dulaglutide and tirzepatide carry a boxed warning for thyroid C-cell tumors (seen in rodents) and are contraindicated with a personal/family history of medullary thyroid cancer or MEN 2.
Drug names
Indications
- Type 2 diabetes — as monotherapy or combination, with diet and exercise (metformin traditional first-line; the liraglutide, dulaglutide and tirzepatide labels include children 10 years and older)
- SGLT2 inhibitors and the incretin agonists for cardiovascular protection in type 2 diabetes (empagliflozin: cardiovascular death with established cardiovascular disease; dapagliflozin: heart-failure hospitalization with cardiovascular disease or multiple risk factors; semaglutide injection and liraglutide: major adverse cardiovascular events with established cardiovascular disease; dulaglutide: the same with established cardiovascular disease or multiple risk factors; tirzepatide and semaglutide tablets: the same in patients at high risk for these events)
- Empagliflozin or dapagliflozin for heart failure and chronic kidney disease, with or without diabetes — both SGLT2 inhibitors are labeled to lower cardiovascular death and heart-failure hospitalization in adults with heart failure and to slow CKD progression (chosen irrespective of A1c in eligible patients)
Mechanism of action
Lower blood glucose by complementary, organ-specific mechanisms: metformin decreases hepatic gluconeogenesis and improves insulin sensitivity; sulfonylureas stimulate glucose-independent insulin secretion from beta cells; DPP-4 inhibitors raise incretin levels to drive glucose-dependent insulin release and suppress glucagon; SGLT2 inhibitors block renal glucose reabsorption to cause glucosuria; and GLP-1 receptor agonists mimic incretin to stimulate glucose-dependent insulin, slow gastric emptying, and promote satiety, with tirzepatide activating both the GIP and GLP-1 receptors.
Therapeutic effects — what you'll see working
Judge success by fasting and post-meal glucose and by the A1c trending toward goal (often < 7%, individualized) — checked at least twice a year. For the newer agents, weight loss and cardiovascular/renal protection are goals in their own right.
- ↓ Fasting & post-meal glucose
- Each subclass lowers glucose through its own lever — less hepatic output, more insulin, or urinary glucose loss. Tracked by self-monitoring/CGM and reflected in the A1c.
- A1c to goal
- The ~3-month average glucose; a common target is < 7%, individualized. Rechecked at least twice a year.
- Weight loss & cardiorenal benefit (newer agents)
- GLP-1 agonists (satiety, slowed emptying) and SGLT2 inhibitors (urinary calorie loss) produce weight loss, while SGLT2 inhibitors reduce heart-failure hospitalization and both classes slow kidney disease — benefits judged by weight, HF status, and eGFR/albuminuria, not glucose alone.
Adverse effects
Sort each harm by the organ its drug acts on: pancreas (sulfonylurea lows), liver/gut (metformin GI + lactic acidosis), kidney (SGLT2 infections, volume, euglycemic DKA), incretin axis (pancreatitis; the thyroid C-cell signal of the GLP-1 and GIP/GLP-1 agonists).
Interactions
Contraindications
Because the class is heterogeneous, the contraindications are agent-specific — each guards against that subclass’s signature danger.
When to hold
Assess before giving — these findings mean hold the dose and act.
Nursing considerations
The RN-specific layer — each action paired with the reason it matters.
Common questions
What are Oral Antidiabetics used for?
How do Oral Antidiabetics work?
What are the serious side effects of Oral Antidiabetics?
When should a nurse hold Oral Antidiabetics, and what safety checks apply?
Conditions treated
Metformin has historically been first-line in type 2 — effective, safe, inexpensive — added when diet and exercise alone miss the goal. Comorbidity now steers the rest: ASCVD → GLP-1 RA and/or SGLT2 inhibitor with proven CV benefit; heart failure → SGLT2 inhibitor; CKD → SGLT2 inhibitor or GLP-1 RA. Know the hypoglycemia-risk subset — sulfonylureas and meglitinides — whose need and dose get reassessed whenever other agents are added.
Same role. "Managing your diabetes is the best way to lower your risk of diabetic retinopathy. That means keeping your blood sugar levels in a healthy range" (NEI). StatPearls: "HbA1c level should be kept below 7%."
On this page the class is taught mainly by its limits, and the limit is a guideline recommendation rather than an opinion. ADA 2026 advises that metformin and glyburide — alone or together — not be used as first-line agents for diabetes in pregnancy, because both cross the placenta to the fetus and may not bring glucose to target on their own; it does not recommend other oral or noninsulin injectable glucose-lowering drugs because they lack long-term safety data. That crossing is the exact property insulin lacks, which is the whole comparison. Doses and titration belong to the class page. One separate rule sits here too: metformin taken for polycystic ovary syndrome or to induce ovulation is stopped by the end of the first trimester (ADA 2026, Rec 15.22, grade A).
Pillar 4: SGLT2 inhibitors reduce HF mortality and hospitalization whether or not the patient has diabetes — the newest pillar of guideline-directed therapy.
Insulin resistance; GLP-1 receptor agonists. StatPearls: "The drugs recommended for treating insulin resistance include metformin, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1(GLP-1) agonists, and pioglitazone." WEGOVY (semaglutide) "is a glucagon-like peptide-1 (GLP-1) receptor agonist" indicated with diet and activity for adults and children 12 and older with obesity, adults with overweight plus a weight-related condition, and cardiovascular risk reduction in adults with established CV disease (label). Once weekly, subcutaneously in the abdomen, thigh or upper arm. NHLBI: thiazolidinediones "can cause liver damage, anemia , heart failure , and blood sugar levels that are too low or too high."
See also
Replace or supplement the body’s own insulin to lower blood glucose. High-alert — hypoglycemia is the #1 risk.
Four smaller groups of type 2 diabetes drugs, each with its own lever: pioglitazone sensitizes tissues to insulin, acarbose and miglitol slow carbohydrate digestion in the gut, repaglinide and nateglinide give a short burst of insulin at meals, and pramlintide adds amylin alongside mealtime insulin. Their signature risks follow the lever: fluid retention and heart failure, gas and diarrhea, hypoglycemia with skipped meals, and severe hypoglycemia with insulin.
Glucagon is the rescue drug for severe hypoglycemia when the patient cannot safely take sugar by mouth; dasiglucagon, a glucagon analog, is used the same way. Given by injection or as a nasal powder, glucagon makes the liver release glucose from glycogen — so it works only if the liver has glycogen to give. It also relaxes the gut and is used as a diagnostic aid in radiology.
Replace thyroid hormone in hypothyroidism, or block its synthesis — or destroy the gland with radioactive iodine — in hyperthyroidism. TSH is the monitoring dial.
Powerful anti-inflammatory/immunosuppressive hormones. Never stop abruptly after prolonged use — taper.
Fludrocortisone replaces the missing mineralocorticoid in primary adrenal insufficiency, so it retains sodium and loses potassium — watch blood pressure, swelling and potassium. Osilodrostat and metyrapone block the last step of cortisol synthesis, and mifepristone (Korlym) blocks cortisol at its receptor; all three can tip a patient into adrenal insufficiency.
Sources
- Ozempic (semaglutide) — thyroid C-cell tumor boxed warning & contraindications (FDA label) — FDA / DailyMed
- Metformin & the antidiabetic drug classes — mechanisms & adverse effects — StatPearls (NCBI)
- The A1C Test & Diabetes — individualized A1C goals — NIDDK (National Institutes of Health)
- Insulin, Medicines, & Other Diabetes Treatments — most people with type 2 diabetes start with metformin — NIDDK (National Institutes of Health)
- JANUVIA (sitagliptin) — FDA label — DailyMed (NLM)
- JARDIANCE (empagliflozin) — ketoacidosis, genitourinary infections, HF/CKD indications (FDA label) — DailyMed (NLM)
- RYBELSUS / OZEMPIC tablets (oral semaglutide) — FDA label — DailyMed (NLM)
- GLUCOTROL XL (glipizide extended-release) — FDA label — DailyMed (NLM)
- GLUMETZA (metformin extended-release) — FDA label — DailyMed (NLM)
- Glipizide tablets — contraindications, hypoglycemia, dosing before meals (FDA label) — DailyMed (NLM)
- Glimepiride tablets — FDA label — DailyMed (NLM)
- Drugs@FDA marketing status — Glucophage, Glumetza, Glucotrol, Amaryl, Januvia, Jardiance, Rybelsus, Ozempic, Farxiga — U.S. FDA (openFDA)
- Sulfonylureas — glucose-independent insulin release — StatPearls (NCBI)
- Glyburide — Beers criteria, prolonged hypoglycemia — StatPearls (NCBI)
- Dipeptidyl Peptidase IV (DPP IV) Inhibitors — low hypoglycemia, weight-neutral — StatPearls (NCBI)
- Sodium-Glucose Transport 2 (SGLT2) Inhibitors — heart failure use — StatPearls (NCBI)
- Glucagon-Like Peptide-1 Receptor Agonists — weight loss — StatPearls (NCBI)
- CDC — Monitoring Your Blood Sugar (A1C testing frequency) — Centers for Disease Control and Prevention
- The use of stems in the selection of INN — -gliflozin, -gliptin, -glutide — World Health Organization
- Potentially inappropriate medications in older adults — short-acting sulfonylureas such as glipizide preferred (Front Public Health, CC BY) — Frontiers in Public Health via PMC
- NESINA (alogliptin) — heart failure in the EXAMINE trial (FDA label) — FDA / DailyMed
- Metformin hydrochloride tablets (Zydus) — lactic acidosis boxed warning, contraindications, contrast and surgery holds (FDA label) — FDA / DailyMed
- FARXIGA (dapagliflozin) — HF/CKD indications, ketoacidosis, volume depletion, surgery hold, lithium (FDA label) — FDA / DailyMed
- Glyburide tablets (Teva) — contraindications incl. bosentan, hypoglycemia, cholestatic jaundice, interactions (FDA label) — FDA / DailyMed
- TRADJENTA (linagliptin) — pancreatitis, bullous pemphigoid, rifampin, renal elimination (FDA label) — FDA / DailyMed
- Saxagliptin tablets (Glenmark) — heart failure (SAVOR), CYP3A4/5 inhibitors, renal function (FDA label) — FDA / DailyMed
- VICTOZA (liraglutide) — thyroid C-cell tumor boxed warning, MACE indication (FDA label) — FDA / DailyMed
- TRULICITY (dulaglutide) — thyroid C-cell tumor boxed warning, MACE indication, oral medications (FDA label) — FDA / DailyMed
- MOUNJARO (tirzepatide) — GIP/GLP-1 receptor agonist, thyroid C-cell tumor boxed warning, oral contraceptives (FDA label) — FDA / DailyMed
Reviewed by Hae Suk Lee, RN
Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.